Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren P Mason

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Neuro-Oncology|July 6, 2014
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsKatherine S Panageas, Anne S Reiner, Fabio M Iwamoto, et al.
Nature Cancer|May 7, 2025
A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesisJulie Bennett, Adrian B Levine, Liana Nobre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Neuro-Oncology|July 6, 2014
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsKatherine S Panageas, Anne S Reiner, Fabio M Iwamoto, et al.
Nature Cancer|May 7, 2025
A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesisJulie Bennett, Adrian B Levine, Liana Nobre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Pageof 12